IGF-1

Most Common Uses

Insulin-like Growth Factor-1 (IGF-1), a peptide hormone, plays a significant role in medical and research applications due to its influence on cell growth and repair. In clinical settings, synthetic IGF-1, such as mecasermin, is used to treat growth failure in children with severe IGF-1 deficiency or growth hormone insensitivity syndromes, such as Laron syndrome. The hormone promotes linear growth by stimulating cartilage development and bone formation. Researchers also explore IGF-1 for its potential in muscle repair and regeneration, particularly in conditions like muscular dystrophy or age-related muscle loss, as it enhances protein synthesis and cell proliferation.

IGF-1 is studied for its neuroprotective effects, with investigations focusing on its ability to support neuronal survival in neurodegenerative diseases like Alzheimer’s or Parkinson’s. In some regions, IGF-1 is examined in experimental therapies for metabolic disorders, leveraging its insulin-like effects to improve glucose uptake. Typically administered via subcutaneous injection, its use is carefully monitored due to regulatory restrictions and potential side effects. Ongoing research continues to explore its broader therapeutic applications across various physiological systems.

Mechanism of Action

IGF-1 works by attaching to special receptors, mainly the IGF-1 receptor (IGF-1R), which sits on the surface of many different cells. When IGF-1 binds to this receptor, it switches on internal signaling pathways such as PI3K-Akt and MAPK, which help cells grow, develop, and stay alive. This process encourages tissue growth, especially in muscle, bone, and cartilage, by boosting protein production and preventing cell death. IGF-1 also acts in ways similar to insulin, helping cells take in and use glucose, which provides energy for growth.

In the brain and nervous system, IGF-1 supports the survival of nerve cells and strengthens connections between them, aiding in protection and learning. Its effects are controlled by IGF-binding proteins (IGFBPs), which adjust how much IGF-1 is available and extend its presence in the blood to about 15 hours. Together, these actions explain IGF-1’s important role in growth, healing, and metabolism, making it a key target for treatments of growth problems and brain-related diseases.

Structure and Pharmacology

IGF-1 is a 70-amino-acid peptide hormone with the sequence Gly-Pro-Glu-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala. Its molecular formula is C331H512N94O101S7, and it has a molecular weight of 7649 g/mol. Structurally similar to insulin, IGF-1 contains three disulfide bonds that stabilize its tertiary structure, enabling effective binding to its receptors. This configuration supports its role in promoting cell growth and repair across various tissues, including muscle, bone, and nervous system cells.

IGF-1 exerts its effects primarily by binding to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor present on many cell types. This interaction activates signaling pathways, such as PI3K-Akt and MAPK, which promote cell proliferation, differentiation, and survival, supporting tissue growth and repair. IGF-1 also facilitates glucose uptake and metabolism, mimicking insulin’s effects, which aids energy provision for growth processes. In the nervous system, it enhances neuronal survival and synaptic plasticity, contributing to neuroprotection.

The peptide’s bioavailability is regulated by IGF-binding proteins (IGFBPs), which extend its half-life to approximately 15 hours when bound, compared to 10–12 minutes for unbound IGF-1. Typically administered via subcutaneous injection in therapeutic settings, such as mecasermin for growth disorders, IGF-1 supports cartilage and bone development in conditions like Laron syndrome. Its pharmacokinetic profile necessitates careful dosing to balance efficacy and potential side effects, with ongoing research exploring its applications in muscle regeneration and neurodegenerative diseases.

Dosages

IGF-1 is administered via subcutaneous injection to treat growth failure in children with severe IGF-1 deficiency or growth hormone insensitivity syndromes, such as Laron syndrome. The typical starting dose for pediatric patients is 0.04 to 0.08 milligrams (mg) per kilogram of body weight, given twice daily. Depending on the patient’s response and tolerance, the dose may gradually increase, up to a maximum of 0.12 mg per kilogram twice daily.

Injections are typically administered in the abdomen, thigh, or upper arm, with sites rotated to minimize irritation. Treatment continues under medical supervision, with adjustments based on growth progress and laboratory monitoring of IGF-1 levels. For research purposes, such as studies on muscle regeneration or neuroprotection, dosing varies widely and is tailored to specific experimental protocols.

Warnings and Cautions

IGF-1 requires careful administration due to potential risks associated with its growth-promoting effects. Patients with known hypersensitivity to IGF-1 or its components should avoid its use, as allergic reactions, including rash or anaphylaxis, may occur and necessitate immediate medical attention. Those with active or suspected malignancies need close monitoring, as IGF-1 may stimulate tumor growth due to its role in cell proliferation. The peptide increases the risk of hypoglycemia, particularly when combined with insulin or other glucose-lowering medications, requiring regular blood sugar monitoring.

Children receiving IGF-1 for growth disorders may experience intracranial hypertension, with symptoms like headache or visual changes, warranting prompt medical evaluation. Pregnant or breastfeeding women should avoid using IGF-1 as safety data in these populations are limited. Common side effects include injection site reactions, joint pain, or swelling, and persistent symptoms should prompt medical review. Long-term use may lead to tonsillar hypertrophy or skeletal abnormalities, particularly in pediatric patients, necessitating ongoing medical oversight. Dose adjustments and patient monitoring are necessary to ensure safe and effective use of IGF-1.

Research & Clinical Trials

Physical Activity, Protein Intake, and IGF-1

This study found that dietary protein intake is positively associated with circulating levels of insulin-like growth factor I (IGF-1) in healthy adults. Specifically, for every additional gram of dietary protein consumed daily, there was a measurable increase in IGF-1 concentration. Physical activity also showed some association with IGF-1 levels, but this effect was smaller and only apparent at moderate levels of activity. Interestingly, very high levels of physical activity did not correlate with higher IGF-1, suggesting that the relationship between exercise and IGF-1 is not straightforward.

The study demonstrated that physical activity did not influence the relationship between dietary protein and IGF-1. That is, whether participants were more or less physically active, the positive effect of dietary protein on IGF-1 remained consistent. Conversely, adjusting for protein intake did not alter the modest association between physical activity and IGF-1. [1]

IGF-1: A Key Growth Hormone

This study concluded that IGF-1 is a key factor in human and animal growth. It is essential for helping the body grow taller, develop bones properly, and support organ growth. IGF-1 works both as a helper of the growth hormone (GH) produced by the pituitary gland and on its own. Evidence from people with Laron syndrome (who have very low IGF-1 and don’t respond to GH) and from mice genetically engineered to lack IGF-1 or GH receptors shows that without IGF-1, growth is severely slowed, organs remain smaller, bones develop more slowly, and other physical problems appear.

Giving IGF-1 from outside the body to children with IGF-1 deficiency greatly speeds up their growth, although it doesn’t always allow them to reach a normal adult height. This effect works even better if some GH is present. Studies comparing GH treatment in children lacking GH suggest that GH may help growth more effectively than IGF-1 alone, probably because GH helps maintain the early bone cells that IGF-1 needs to work properly. [2]

IGF-1 & Cell Growth

This study concluded that IGF-1 is a key protein that mediates the effects of growth hormone (GH) and plays a critical role in cell growth, development, and survival throughout life. IGF-1 works through a complex network of receptors, binding proteins (IGFBPs), and related peptides, which regulate its availability and activity. Alterations in IGF-1 levels are linked to a variety of health conditions, including growth deficiencies, cancers, diabetes, liver disease, and sepsis. IGF-1 is also widely misused as a performance-enhancing drug in sports.

The study emphasizes that while IGF-1 is central to normal growth and tissue maintenance, its measurement is complicated by binding proteins that reduce detectable levels in blood samples, making accurate quantification challenging. IGF-1 levels can serve as a biomarker for diseases such as Laron syndrome, acromegaly, breast and prostate cancers, and metabolic disorders. Therapeutically, recombinant IGF-1 is used to treat severe growth deficiencies, but its analogues vary in potency and half-life. The research also highlights the challenges and partial successes of detecting IGF-1 abuse in athletes, showing that biomarker-based tests using IGF-1 concentrations can improve detection sensitivity. [3]